Is Tenax Therapeutics, Inc. (TENX) a Buy, Sell, or Hold?
NASDAQ : TENX
Tenax Therapeutics, Inc.
$1.375 USD
-$12.06 (-89.77%)
- Volume
- 64.26M
- Average Volume
- 1.03M
- Market Capitalization
- $36.47M
- P/E Ratio
- -0.92
- Dividend Yield
- 0.00%
- Price Target
- $31.00
- Year High
- $19.40
- Year Low
- $1.31
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $15.07
Company Overview
NASDAQ
Christopher T. Giordano
Biotechnology
Healthcare
TENX
15
US
USD
Liquidity Metrics
0.00
15.07
15.07
14.61
0.00
Sales & Valuation
-$
0.00
0.62
-0.79
-0.90
Profitability
-$1.34
-$52.6M
0.00%
0.00%
-61.55%
-53.31%
P/E Metrics
-0.92
0.02
0.02
Analyst Price Target & Rating
$31.00
$40.00
$5.00
2/5
6 Analysts
-95.56%
Financial Health Scores
21.22
1/9
$113.59M
$121.66M
$8.07M
-$65.84M
Key Metrics (TTM)
$238.52M
0.00
-3.62
15.07
-61.55%
-60.40%
-9.49%
-12.91%
0 days
Company Executives
| Name | Title |
|---|---|
| Thomas A. McGauley | Principal Financial Officer & Principal Accounting Officer |
| Thomas R. Staab | Chief Financial Officer |
| So-Young Kim | Executive Vice President of Clinical Development & Strategy |
| Doug Randall | Chief Business Officer |
| Stuart Rich | Chief Medical Officer & Director |
| Christopher T. Giordano | Chief Executive Officer, President & Director |
| Douglas Hay | Executive Vice President of Regulatory Affairs |
| Timothy G. Healey | Chief Commercial Officer |
Poll Results
No votes yet today — be the first to share your view!
About Tenax Therapeutics, Inc. (NASDAQ:TENX) Stock
Tenax Therapeutics, Inc. is a specialized pharmaceutical enterprise dedicated to discovering, advancing, and bringing to market therapies for cardiovascular and pulmonary conditions throughout the United States and Canada. Its product pipeline features TNX-103 and TNX-102 (levosimendan), both of which have successfully completed Phase II clinical trials. These compounds are being developed to manage pulmonary hypertension, particularly that linked to heart failure with preserved ejection fraction (HFpEF), as well as other forms of associated pulmonary hypertension. Additionally, the company is progressing TNX-201 (imatinib), a tyrosine kinase inhibitor, designed to treat pulmonary arterial hypertension. Founded in 1967, the organization was initially known as Oxygen Biotherapeutics, Inc. u ... ntil its rebranding to Tenax Therapeutics, Inc. in September 2014. The company maintains its corporate headquarters in Morrisville, North Carolina.
Tenax LEVEL Trial Misses Primary Goal, but Subgroup Data Bolsters Levosimendan Case
2026-08-11 02:02:44
Tenax Therapeutics NASDAQ: TENX reported that its Phase III LEVEL trial of oral levosimendan in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction, or PH-HFpEF, did not meet its primary endpoint, though the company said subgroup, biomarker and hemodynamic findings will inform its next steps in the program.
Tenax Therapeutics Stock Dives as It Faces Heart Drug Study Setback
2026-08-10 12:02:44
Tenax Therapeutics Inc. (NASDAQ:TENX) stock is trading lower on Monday after the company reported topline results from its Phase 3 LEVEL study evaluating oral levosimendan (TNX-103) in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF).
2026-08-10 10:58:28
Tenax Therapeutics, Inc. (TENX) Discusses Phase III LEVEL Trial Results for Oral Levosimendan in HFpEF Patients Transcript
Tenax Therapeutics' heart drug misses main goal in study, shares plunge
2026-08-10 07:12:21
Tenax Therapeutics said on Monday its experimental heart drug failed to meet the main goal of a late-stage study.
2026-08-10 07:00:00
TNX-103 did not meet statistical significance on the primary endpoint of improvement in 6-minute walk distance versus placebo
Tenax Therapeutics, Inc. (NASDAQ:TENX) Receives Consensus Rating of “Moderate Buy” from Brokerages
2026-08-10 04:15:28
Tenax Therapeutics, Inc. (NASDAQ: TENX - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the nine brokerages that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, seven have given a buy rating and one has assigned a strong buy rating to the
Tenax Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
2026-07-31 07:00:00
Company expects to report topline data from Phase 3 LEVEL clinical trial in August 2026 CHAPEL HILL, N.C., July 31, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”) today reported financial results for the quarter ended June 30, 2026 and provided an update on its corporate progress.
2026-07-21 10:55:19
The mean of analysts' price targets for Tenax Therapeutics (TENX) points to a 121.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Frequently Asked Questions
-
What is the current Tenax Therapeutics, Inc. (TENX) stock price?
-
Tenax Therapeutics, Inc.(NASDAQ:TENX) stock price is $1.375 in the last trading session. During the trading session, TENX stock reached the peak price of $19.4 while $1.31 was the lowest point it dropped to. The percentage change in TENX stock occurred in the recent session was --89.77% while the dollar amount for the price change in TENX stock was -$12.06.
-
TENX's industry and sector of operation?
-
The NASDAQ listed TENX is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of TENX?
-
Thomas A. McGauley | Principal Financial Officer & Principal Accounting Officer
Thomas R. Staab | Chief Financial Officer
So-Young Kim | Executive Vice President of Clinical Development & Strategy
Doug Randall | Chief Business Officer
Stuart Rich | Chief Medical Officer & Director -
How many employees does TENX have?
-
Number of TENX employees currently stands at 15. TENX operates from 101 Glen Lennox Drive, Chapel Hill, NC 27517, US.
-
Link for TENX official website?
-
Official Website of TENX is: https://www.tenaxthera.com
-
How do I contact TENX?
-
TENX could be contacted at phone #919 855 2100 and can also be accessed through its website. TENX operates from 101 Glen Lennox Drive, Chapel Hill, NC 27517, US.
-
How many shares of TENX are traded daily?
-
The average number of TENX shares traded daily for last 3 months was 1.03M.
-
What is the market cap of TENX currently?
-
The market value of TENX currently stands at $36.47M with its latest stock price at $1.375